Education
About Us
Working with TipRanks
Follow Us
Insulet (PODD)
NASDAQ:PODD
PODD Stock Chart & Stats
$251.22
$3.66(1.38%)
At close: 4:00 PM EST
$251.22
$3.66(1.38%)
Day’s Range― - ―
52-Week Range$230.05 - $354.88
Previous CloseN/A
Volume86.50K
Average Volume (3M)725.70K
Market Cap
$18.05B
Enterprise Value$17.95B
Total Cash (Recent Filing)$757.40M
Total Debt (Recent Filing)$1.03B
Price to Earnings (P/E)72.9
Beta0.65
Next Earnings
Feb 18, 2026EPS Estimate
1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.24
Shares Outstanding70,346,900
10 Day Avg. Volume1,177,953
30 Day Avg. Volume725,697
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)15.10
Price to Sales (P/S)8.83
P/FCF Ratio59.90
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.12
Enterprise Value/Gross Profit9.96
Enterprise Value/Ebitda39.77
Forecast
1Y Price Target
$368.41Price Target Upside46.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Patient Adoption And Market PenetrationRapid patient uptake of the Omnipod platform, driven by attractive form factor and pharmacy access, is supporting above-market revenue growth and expanding the installed base.
Product Pipeline And New LaunchesPlanned launches including Omnipod 6 with an adaptive algorithm and broad CGM compatibility in 2027, plus a fully closed-loop Type 2 system in 2028, could broaden product appeal and open new patient segments.
R&D Investment And Addressable MarketA significant multi-year R&D commitment together with a large addressable market and targeted international expansion underpins prospects for revenue growth and margin improvement.
Bears Say
Competitive EncroachmentCompetitors introducing similar tubeless delivery options risk narrowing the company's form-factor and pharmacy distribution advantages, which could pressure future patient share gains.
Sales Visibility And Data ClaritySampling programs and specialty pharmacy order patterns are complicating script trend analysis and can obscure true underlying adoption, increasing uncertainty around sales forecasts.
Valuation SensitivityCurrent valuation multiples appear to price in much of the positive outlook, which could limit upside if execution falls short of elevated expectations.
Insulet News
PODD FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was $230.05 and its highest was $354.88 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is $18.05B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Feb 18, 2026 which is in 13 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Nov 06, 2025. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.1.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.46.
How many shares outstanding does Insulet have?
Insulet has 70,346,900 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of $1.24 in its last earnings report, beating expectations of $1.14. Following the earnings report the stock price went up 2.85%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in PODD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$368.41 (46.65% Upside)
$368.41 (46.65% Upside)
Blogger Sentiment
Bullish
PODD Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $242.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.6%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.92%
12-Months-Change
Fundamentals
Return on Equity
19.68%
Trailing 12-Months
Asset Growth
0.13%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Company Deck
PODD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record revenue growth, particularly in international markets and the U.S. Type 2 segment. Operating margins have improved, and the company has successfully managed its debt. However, there are increased R&D expenses and higher interest expenses due to debt restructuring.View all PODD earnings summariesPODD Revenue Breakdown
72.86% U.S. Omnipod
25.27% International Omnipod
1.88% Drug Delivery
PODD Stock 12 Month Forecast
Average Price Target
$368.41
▲(46.65% Upside)
Technical Analysis
Ownership Overview
0.38% Insiders
39.48% Mutual Funds
0.79% Other Institutional Investors
32.55% Public Companies and Individual Investors